News

Jan 4 2018

Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy

Jan 4 2018

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced positive interim data from the first dose cohort of ASPIRO, a Phase 1/2 clinical trial of AT132 in patients with X-Linked Myotubular Myopathy (XLMTM).  ASPIRO is a multicenter, multinational, open-label, ascending dose study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years of age.

READ MORE

Dec 20 2017

Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 20 2017

STAMFORD, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments. The company expects to complete the NDA submission in early 2018.

READ MORE

Dec 18 2017

TransEnterix Announces Global SurgiBot System Agreement

Dec 18 2017

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that the Company has entered into an agreement with Great Belief International Limited (GBIL), to advance the SurgiBot System towards global commercialization. The SurgiBot System is the single-port, robotically enhanced laparoscopic surgical platform developed by TransEnterix. This agreement transfers ownership of the SurgiBot System assets, while the Company retains the option to distribute or co-distribute the SurgiBot System outside of China. Upon completion of the transfer of all SurgiBot System assets, GBIL will have the System manufactured in China and obtain Chinese regulatory clearance from the China Food and Drug Administration (“CFDA”), while entering into a nationwide distribution agreement with China National Scientific and Instruments and Materials Company (CSIMC) for the Chinese market. Being the largest medical device distribution company in China, CSIMC will help GBIL maximize the commercial potential of the SurgiBot System in the Chinese market, and optimize post-sale services to Chinese hospitals. The Company retains the right to commercialize the SurgiBot System outside of China after manufacturing has been established and the necessary regulatory approvals have been obtained.

READ MORE

Dec 15 2017

Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for Treatment of Raised Seborrheic Keratoses (SKs)

Dec 15 2017

MALVERN, Pa., Dec. 15, 2017 — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number with age. The condition is more prevalent than acne, psoriasis and rosacea combined.

READ MORE

Dec 7 2017

Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash

Dec 7 2017

PLYMOUTH, Minn., Dec. 07, 2017 (GLOBE NEWSWIRE) — Entellus Medical, Inc. (NASDAQ:ENTL) announced today a definitive merger agreement by which Stryker Corporation (NYSE:SYK) will acquire Entellus in an all cash transaction for $24.00 per share, or an equity value of approximately $662 million. The Entellus Board of Directors unanimously approved entering into the agreement.

READ MORE

Nov 14 2017

Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

Nov 14 2017

STAMFORD, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that it has entered into a global collaboration with Bayer to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancers.

Under the terms of the agreement, Loxo Oncology will receive a $400M upfront payment. Loxo Oncology is eligible for $450M in milestone payments upon larotrectinib regulatory approvals and first commercial sale events in certain major markets and an additional $200M in milestone payments upon LOXO-195 regulatory approvals and first commercial sale events in certain major markets.

READ MORE

Nov 13 2017

Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials

Nov 13 2017

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today the completion of a $107 million Series C financing. This financing brings the total equity capital that the company has raised since its inception in 2015 to $227 million.

The proceeds from this financing will be used for the advancement of Arcus’s clinical programs for AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody. Earlier this month, Arcus initiated a phase 1 trial of AB928 in healthy volunteers and Arcus plans to initiate a phase 1/2 trial of AB928 in combination with AB122 in cancer patients during the first half of 2018. Also in November, Arcus initiated a phase 1 trial of AB122 in cancer patients in Australia. Data from the AB122 trial will be available in 2018 and Arcus plans to evaluate AB122 in combination with its other product candidates, in addition to AB928, in the future. The proceeds raised will also allow Arcus to advance at least two additional product candidates into clinical development, including AB680, a first-in-class small molecule CD73 inhibitor, and AB154, a TIGIT antibody.

The financing was led by GV (formerly Google Ventures), with participation from new investors, including Wellington Management Company LLP, EcoR1 Capital, BVF Partners L.P., Decheng Capital, Hillhouse, Aisling Capital and entities affiliated with Leerink Partners. Arcus’s existing investors, including The Column Group, Foresite Capital, Invus Opportunities, DROIA, Celgene Corporation and Taiho Ventures, also participated in the financing.

READ MORE

Nov 8 2017

Meet a VC: Steve Elms & Drew Schiff of Aisling Capital

Nov 8 2017

Recently, Jill Malandrino, Global Markets Reporter, Nasdaq sat down with Steve Elms and Drew Schiff, Managing Partners at Aisling Capital to discuss their investment focus and strategies.

http://www.youtube.com/watch?v=hE92Z0heUCE

READ MORE

Nov 2 2017

Aisling Capital Closes $280 Million Fund to Improve Global Health

Nov 2 2017

NEW YORK, Nov. 2, 2017 /PRNewswire/ — Aisling Capital, a late-stage life sciences investment firm that partners with companies to successfully bring novel medical therapies to market, today announced the closing of its newest fund, with $280 million in committed capital. The capital raised will allow Aisling Capital to continue helping clinical stage ventures improve global health by more rapidly bringing breakthrough medical treatments to market.

Aisling Capital will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization. Portfolio companies gain access to Aisling Capital’s strategic counsel and deep experience in both financial and medical fields, along with its unmatched network that extends from regulatory organizations to leading pharmaceutical companies and financial institutions. Aisling Capital is determined to increase the number of quality medical therapeutics in development and get treatments into the hands of people who need it.

READ MORE

Nov 2 2017

Aisling Capital Closes New Fund to Improve Global Health

Nov 2 2017

By Steve Elms and Andrew Schiff, M.D., Managing Partners, Aisling Capital

Today, we have the pleasure of announcing the close of our most recent round of funding at Aisling Capital, a $280 million late-stage venture capital fund aimed at accelerating breakthrough medical treatments to market and improving global health.

One thing we are continually impressed by at Aisling is the constant evolution of both the biotech industry and medical science, especially in regard to improving patients’ lives. We would like to think that thanks in part to our work, Aisling has helped to increase the number of quality medical treatments in development — which today is larger than ever before.

As experience from across Wall Street and medicine came together in 2000 to form what would become Aisling, we observed a pattern of venture capital supporting company formation and raw scientific research. Ultimately however, these companies required substantial additional capital and financial strategy to bring drugs through the clinic and onto the market.

We continue to execute on this opportunity to invest in both private and public companies with therapeutics in the clinical stage, the final and most expensive leg of the relay race that is drug development. With our partners’ combination of financial, operational and clinical experience, we decided to focus on helping companies in this final leg of the race — helping to get treatments into the hands of people who need it.

The Aisling approach of identifying and investing in promising biotech companies in the later stages of drug development has generally served us well. Over the last 17 years, we have witnessed — and in many cases been a catalyst for — medical innovations in areas ranging from the treatment of cancer and infectious disease, to body contouring procedures and innovative dermatology products.

While Aisling has a history of thinking holistically about the intersection of medical science and financial strategy for late-stage startups, the industry at large now seems to be moving in this direction also. We have seen a maturing among biotech entrepreneurs. Management teams are now more focused on ensuring their investors have the right financial expertise to help them fund the final stages of drug development. Rather than spending significant resources experimenting prior to moving into clinical stages, most companies now start on a path toward the development of a treatment or medication at the outset or shortly after.

Today, every biotech startup must develop treatments that generate significant upside for patient care through more impact on disease, fewer side effects, and a shift away from toxic therapies toward a personalized approach. We are pleased to have the resources to continue to be a significant participant in our market and help the companies we invest in achieve this goal. We are also grateful to have excellent relationships with likeminded co-investors and work collaboratively with them to provide the support our portfolio companies need to solve some of the world’s most persistent medical challenges.

On behalf of Aisling Capital, we want to thank all of our management teams for their unrelenting and unwavering efforts to advance not only their drugs in development, but the sector overall. Of course, we serve at the pleasure of our limited partners and are grateful for their trust, confidence and continued support, and are committed to being good shepherds of their capital by continuing our mission to accelerate breakthrough medical treatments to market.